Prospective, Randomized Evaluation of Immediate Versus Deferred Angioplasty in Patients with High Risk Acute Coronary Syndromes RK Riezebos 1, E Ronner.

Slides:



Advertisements
Similar presentations
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Advertisements

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
VA NQWISH Veterans Affairs Non-Q Wave Infarction Strategies In-Hopsital Trial.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
DEFER STUDY: 5-YEAR FOLLOW-UP A Multicenter Randomized Study
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Partner meeting Aprile, Alberto Cremonesi.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
LBCT March 29, 08 ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Dr.Ali Eshraghi MD Interventional Cardiologist Non STE ACS  Angiographic Findings: 34% 3VD 28%2VD 26%SVD 10%LMCAD Culprit lesion charactristic: eccentric,scalloped,evidence.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Invasive Versus Conservative Strategy in Patients Aged 80 years or Older with NSTEMI or Unstable Angina(After Eighty study) Nicolai Tegn, Michael Abdelnoor,
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
The European Society of Cardiology Presented by Dr. Saman Rasoul
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
ClinicalTrials.gov Identifier NCT
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
AF and PCI in Practice.
Late Breaking Clinical Trials
European Society of Cardiology 2003
Invasive versus conservative treatment in unstable coronary syndromes
Figure 1 PCI strategies in patients with STEMI and multivessel disease
Published in the European Heart Journal
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
The European Society of Cardiology Presented by RJ De Winter
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
American College of Cardiology Presented by Dr. Michel R. Le May
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
European Heart Journal Advance Access
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Javier Escaned et al. JCIN 2018;11:
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

Prospective, Randomized Evaluation of Immediate Versus Deferred Angioplasty in Patients with High Risk Acute Coronary Syndromes RK Riezebos 1, E Ronner 1, E Ter Bals 1, T Slagboom 1, F Kiemeneij 1, G Amoroso 1, MS Patterson 1, JG Tijssen 2, MJ Suttorp 3, GJ Laarman 1 1 Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands 2 Amsterdam Medical Center, Amsterdam, The Netherlands 3 St Antonius Hospital, Nieuwegein, The Netherlands Current controlled trial number: ISRCTN

Introduction Current guidelines recommend an early invasive strategy in high risk NSTE-ACS Current guidelines recommend an early invasive strategy in high risk NSTE-ACS The precise timing of early PCI is controversial. The precise timing of early PCI is controversial.  Immediate PCI may prevent (spontaneous) cardiac events  Deferred PCI may lead to less peri-procedural complications

OPTIMA trial Optimal timing of PCI in unstable angina Optimal timing of PCI in unstable angina To compare immediate with 24–48 hours deferred PCI in the early invasive management of NSTE-ACS To compare immediate with 24–48 hours deferred PCI in the early invasive management of NSTE-ACS Hypothesis: In high risk NSTE-ACS immediate PCI reduces cardiac events Hypothesis: In high risk NSTE-ACS immediate PCI reduces cardiac events

Patients Patients with high risk NSTE-ACS Patients with high risk NSTE-ACS No indication for urgent PCI No indication for urgent PCI Immediate coronary angiography Immediate coronary angiography Culprit lesion amenable for PCI Culprit lesion amenable for PCI

Randomized treatments Randomization in cathlab after angiography Randomization in cathlab after angiography Immediate PCI Immediate PCI  PCI of culprit lesion in same session Deferred PCI Deferred PCI  PCI of culprit lesion after repeat angiography hours later Triple antiplatelet therapy Triple antiplatelet therapy  Abciximab, clopidogrel and aspirin

n No significant CAD55 CABG is better treatment27 ISR9 Clinically driven immediate PCI8 Culprit lesion not amenable for PCI6 CTO4 Acute coronary angiography 251 Patients randomized 142 Immediate PCI 73 Deferred (24-48h) 69 Angiographic exclusion 109 Flow chart

Time from randomization to PCI

Clinical events at 30 days Immediate PCI (n=73) Deferred PCI (n=69) p Mortality0(0)0 MI44(60)26(37)0.007 MI at randomization 16(22)12(17)0.5 MI after randomization 28(38)14(20)0.03 Unplanned revascularization1(1)3(4)0.3 Composite endpoint44(60)27(39)0.01

Primary endpoint at 30 days

Infarct size during initial hospitalization % peak CKMB: P<0.01 CKMB (median): (ng/L)

Conclusions Immediate PCI increased the rate of periprocedural MI compared to a cooling down strategy of deferred PCI Immediate PCI increased the rate of periprocedural MI compared to a cooling down strategy of deferred PCI The results of the study suggest that there is no need to rush to PCI in non-refractory high risk NSTE-ACS patients The results of the study suggest that there is no need to rush to PCI in non-refractory high risk NSTE-ACS patients